Business Results
First Nine Months of Fiscal Year Ending March 31, 2018

The Sysmex Group has adopted International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.

Sysmex Corporation

February 6, 2018

Financial Highlights



	First nine months of fiscal year ending March 31, 2018	First nine months of fiscal year ended March 31, 2017
1USD	**¥111.7**	¥106.6
1EUR	**¥128.5**	¥118.0
1CNY	**¥16.6**	¥16.0

(Billions of yen)

	First nine months of fiscal year ending March 31, 2018 Results	Ratio	First nine months of fiscal year ended March 31, 2017 Results	Ratio	**YOY (Previous period = 100%)**
Net sales	**202.5**	**100%**	180.7	100%	**112.0%**
Cost of sales	**87.3**	**43.1%**	76.2	42.2%	**114.6%**
SG&A expenses	**59.0**	**29.1%**	54.8	30.3%	**107.6%**
R&D expenses	**11.9**	**5.9%**	11.3	6.3%	**104.7%**
Other income (expenses)	**0.3**	**0.2%**	0.8	0.5%	**40.9%**
Operating profit	**44.5**	**22.0%**	39.1	21.7%	**113.8%**
Profit attributable to owners of the parent	**30.5**	**15.1%**	31.9	17.7%	**95.6%**

- **Net sales:** Sales increased on both a local currency and yen basis in all geographic regions.
- **Operating profit:** Profit rose, as higher sales pushed up gross profit and due to the positive impact of yen depreciation year on year.
  Exchange rate fluctuations raised net sales ¥9.09 billion and operating profit ¥1.62 billion. At the exchange rates prevailing one year earlier, net sales would have been up 7.0% year on year, and operating profit up 9.7%.
- **Profit attributable to owners of the parent:** Profit was down, reflecting the impact in the second quarter of the previous year of the revision of a tax treaty with Germany.
- **Exchange loss (gains):** Loss of ¥0.31 billion (¥1.90 billion in the first nine months of the previous fiscal year)
- **Capital expenditure (tangible):** ¥7.44 billion
  Depreciation and amortization: ¥10.89 billion

Breakdown of Net Sales and Operating Profit

(Billions of yen)

Net Sales

Note: FX impact excluded from sales by geographic region



Operating Profit



Net Sales by Geographic Region

(Billions of yen)

Net Sales by Geographic Region (Sales to External Customers)

		First nine months of fiscal year ending March 31, 2018		First nine months of fiscal year ended March 31, 2017		YOY (Previous period = 100%)	
		Results	Ratio	Results	Ratio	(Yen)	(Local currency)
Sales		202.5	100%	180.7	100%	112.0%	-
Region	Americas	44.1	21.8%	40.6	22.5%	108.7%	103.7%
	EMEA	54.5	26.9%	47.2	26.1%	115.5%	106.1%
	China	52.2	25.8%	45.4	25.1%	115.1%	110.3%
	AP	17.9	8.9%	14.7	8.2%	121.4%	(116.0%)
	Japan*	33.6	16.6%	32.7	18.1%	102.8%	-

* Includes sales to IDEXX and other external customers

Exchange Rates

	First nine months of fiscal year ending March 31, 2018	First nine months of fiscal year ended March 31, 2017
1USD	¥111.7	¥106.6
1EUR	¥128.5	¥118.0
1CNY	¥16.6	¥16.0

- **Percentage of Sales in Emerging Markets**

First nine months of fiscal year ended March 31, 2017 — **First nine months of fiscal year ending March 31, 2018**



Sales by Business

(Billions of yen)

	First nine months of fiscal year ending March 31, 2018 Results	Ratio	First nine months of fiscal year ended March 31, 2017 Results	Ratio	YOY (Previous period = 100%)	Reference: YOY at previous year's rate
Hematology	126.5	62.5%	114.3	63.2%	110.8%	105.5%
Urinalysis	15.1	7.5%	11.7	6.5%	129.2%	123.5%
HU Business	141.7	70.0%	126.0	69.7%	112.5%	107.2%
Immunochemistry	7.9	3.9%	5.8	3.2%	134.8%	131.4%
Clincal Chemistry	2.5	1.3%	2.5	1.4%	101.2%	98.3%
Hemostasis	31.6	15.6%	31.2	17.3%	101.3%	96.9%
ICH Business	42.1	20.8%	39.6	21.9%	106.3%	102.1%
Core Businesses	183.8	90.8%	165.6	91.6%	111.0%	106.0%
FCM Business	1.1	0.6%	1.2	0.7%	90.9%	85.2%
LS Business	6.0	3.0%	3.1	1.7%	190.4%	182.1%
Others	-	-	-	-	-	-
Next Core Businesses	7.1	3.5%	4.4	2.4%	161.9%	154.3%
Others*	11.4	5.7%	10.6	5.9%	107.7%	104.2%
Total Net Sales	202.5	100.0%	180.7	100.0%	112.0%	107.0%

*Others: Clinical laboratory information systems, sales of third-party products, etc.

HU Business: Hematology and urinalysis fields
ICH Business: Immunochemistry, clinical chemistry and hemostasis fields
FCM Business: Flow cytometry field
LS Business: Life science field

Geographic Segment Information: Americas





*Revision in intragroup transaction prices

(Billions of yen)	First nine months of fiscal year ending March 31, 2018	First nine months of fiscal year ended March 31, 2017	YOY (Previous period = 100%) (Yen basis)	(Local currency basis)
Sales	**44.1**	40.6	**108.7%**	103.7%
Operating Profit*	**3.8**	2.4	**153.1%**	146.2%

- **Sales rose, thanks to growth in hematology reagents and services in the United States and sales to a large commercial lab in Canada, although sales fell in Central and South America.**
- **Operating profit grew substantially, boosted by an improved cost of sales ratio as reagents and services made up a higher percentage of sales, and a revision in intragroup transaction prices.**

Local Currency Basis

- **United States:** Sales grew, as sales of hematology reagents and services increased due to growth in the installed instrument base, despite delay in instruments sales to some customer sites.
- **Canada:** Sales rose, due to the hematology instruments sales to a large commercial lab.
- **Central and South America:** Despite a recovery in Brazil and other countries, sales were down due to the impact of a large-scale tender acquired in Mexico in the previous fiscal year.

Geographic Segment Information: EMEA*





*Revision in intragroup transaction prices

*Europe, the Middle East and Africa

(Billions of yen)	First nine months of fiscal year ending March 31, 2018	First nine months of fiscal year ended March 31, 2017	YOY (Previous period = 100%) (Yen basis)	(Local currency basis)
Sales	**54.5**	47.2	**115.5%**	106.1%
Operating Profit*	**4.3**	3.6	**117.8%**	108.2%

- **Sales were up due to higher sales in France, Russia and Turkey, as well as acquisition of OGT, despite the impact of sales delays in the United Kingdom as a result of Brexit.**
- **Operating profit rose, due to an improved cost of sales ratio stemming from higher reagent sales in emerging markets, despite the impact of higher SG&A expenses due to acquisition of OGT and the shift to a direct sales structure in the urinalysis field in France and other countries.**

Local Currency Basis

- **Five major countries:** Despite the ongoing impact of sales delays in the United Kingdom, sales were up as a result of direct sales in France in the urinalysis and hemostasis fields.
- **Eastern Europe, Russia:** Sales rose due to higher sales of reagents in Russia, owing mainly to growth in the installed instrument base in the hematology field.
- **Middle East, Africa:** Sales fell due to the impact of large tenders in the previous fiscal year.
- **Other parts of Europe:** Sales grew, thanks to increased reagent sales in Turkey due to a higher installed instrument base in the hematology field.

Geographic Segment Information: China





*Revision in intragroup transaction prices

(Billions of yen)	**First nine months of fiscal year ending March 31, 2018**	First nine months of fiscal year ended March 31, 2017	**YOY (Previous period = 100%) (Yen basis)**	(Local currency basis)
Sales	**52.2**	45.4	**115.1%**	110.3%
Operating Profit*	**6.0**	2.5	**235.0%**	225.3%

- **Sales expanded, as an increase in the installed instrument base caused reagent sales to rise in all fields, mainly in immunochemistry and hemostasis. (Also contributing was an increase in reagent prices to distributors, due to a shift toward the provision of direct services.)**
- **Service-related expenses climbed due to the transition to direct services, but operating profit grew substantially, due to a revision in intragroup transaction prices and a rising percentage of reagent sales.**

- **Hematology:** Sales increased due to favorable reagent sales.
- **Hemostasis:** Sales were flat, as favorable performance in fibrin reagents compensated for lower instrument sales.
- **Urinalysis:** Sales grew substantially, thanks to robust sales of the new UN-Series.
- **Immunochemistry:** Sales rose considerably, as a result of a steady increase in reagent sales, centered on markers for infectious diseases, stemming from an expanded installed instrument base.

Geographic Segment Information: AP



(Billions of yen)	First nine months of fiscal year ending March 31, 2018	First nine months of fiscal year ended March 31, 2017	YOY (Previous period = 100%) (Yen basis)
Sales	**17.9**	14.7	**121.4%***
Operating Profit*	**2.2**	1.5	**138.2%**

- **Sales rose due to higher sales in South Asia from the acquisition of tenders in India and Bangladesh, as well as to the impact of a shift to direct sales in Taiwan (May 2017).**
- **Although SG&A expenses increased, operating profit rose due to the move to direct sales in Taiwan, the impact of a revision in intragroup transaction prices and higher gross profit, stemming from increased reagent sales.**

* Excluding the impact of exchange rates on currencies in the AP region, sales would have been up 16.0%.

- **South Asia:** Sales rose due to the acquisition of government tenders in India and Bangladesh.
- **South Korea, Taiwan:** In addition to the shift to direct sales in Taiwan, sales were up thanks to favorable sales of instruments in South Korea in the hematology and urinalysis fields.
- **Oceania:** Sales fell, due to the impact of large-scale project in Australia in the previous fiscal year.

Geographic Segment Information: Japan



*Revision in intragroup transaction prices

(Billions of yen)	First nine months of fiscal year ending March 31, 2018	First nine months of fiscal year ended March 31, 2017	YOY (Previous period = 100%)
Sales	106.2	103.1	103.1%
Sales to External Customers	33.6	32.7	102.8%
Japan	32.2	30.8	104.5%
IDEXX and Others	1.3	1.8	74.1%
Intra-Area Transfers	72.6	70.3	103.2%
Operating Profit*	29.8	27.2	109.5%

- **Yen depreciation positively affected intra-area transfers to Group affiliates overseas, pushing up sales. Higher sales of reagents in Japan also helped boost sales throughout the segment.**
- **A revision in intragroup transaction prices caused the cost of sales ratio to worsen, but operating profit rose due to efforts to constrain SG&A expenses.**

- **Japan:** Sales rose as a result of higher reagent sales in the hemostasis and immunochemistry fields.
- **IDEXX and others:** Sales of instruments for veterinary to IDEXX were down.

Consolidated Earnings Forecast

Note: No changes subsequent to November 2017 announcement

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2018

Net sales: ¥280. billion

Operating profit: ¥58.0 billion

Operating margin: 20.7%

Profit attributable to owners of the parent: ¥41.5 billion

Profit attributable to owners of the parent to net sales: 14.8%

Planned Investment	Capital expenditure: ¥18.0 billion (Tangible only)	Depreciation and amortization: ¥14.0 billion	R&D expenditure: ¥17.5 billion

● Assumed Exchange Rates

	Full Year (Announced in May 2017)	Full Year (Revised in Nov. 2017)	Second Half (Revised in Nov. 2017)	Previous Year (Fiscal year Ended March 31, 2017)
1 USD	¥110.0	¥110.5	¥110.0	¥108.4
1 EUR	¥115.0	¥128.1	¥130.0	¥118.8
1 CNY	¥16.0	¥16.5	¥16.5	¥16.1



Sysmex Corporation

We Believe the Possibilities.

Forward-Looking Statements

This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

Sysmex Corporation

Contact:
IR & Corporate Communication Dept.
Corporate Communication Div.
Phone: +81-78-265-0500
Email: info@sysmex.co.jp
www.sysmex.co.jp/en